<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563953</url>
  </required_header>
  <id_info>
    <org_study_id>SOLTI0702</org_study_id>
    <secondary_id>2007-001428-11</secondary_id>
    <nct_id>NCT00563953</nct_id>
  </id_info>
  <brief_title>Caelyx as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease and/or Age Over 65 Years</brief_title>
  <acronym>CAPRICE</acronym>
  <official_title>A Phase II, Open-Label, Multicenter Clinical Trial of Pegylated Liposomal Doxorubicin (Caelyx®) as Primary Treatment for Patients With Breast Cancer and a History of Heart Disease or Age Over 65 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOLTI Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SOLTI Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter study of a primary chemotherapy regimen in breast cancer patients at
      risk of developing cardiotoxicity. The aim of the study is to evaluate the response rate at
      surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, uncontrolled, open label, multicenter study of a primary chemotherapy
      regimen consisting of four cycles of liposomal pegylated doxorubicine 35 mg/m² IV plus
      cyclophosphamide 600 mg/m² on Day 1 every 4 weeks followed by paclitaxel 80 mg/m²/week for 12
      weeks before surgery in breast cancer patients at risk of developing anthracycline-induced
      cardiotoxicity.

      Surgery (tumorectomy, quadrantectomy, or mastectomy plus lymphadenectomy) will be performed 2
      to 5 weeks after the last primary chemotherapy infusion.

      Patients with &gt; 10% of hormone receptor-positive cells will receive appropriate hormone
      therapy according to menopausal status.

      Patients treated with breast-conserving surgery will receive radiation therapy to the mammary
      gland.

      Patients with T4 tumors or significant axillary involvement (≥ ypN2) will receive radiation
      therapy to the breast or chest wall and to the lymph node chains.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response (pCR). pCR is defined as the absence of invasive cancer in the surgical breast specimen. This definition includes evidence of carcinoma in situ only.</measure>
    <time_frame>At surgery.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response rate (complete plus partial responses). Clinical response will be assessed by imaging using the WHO criteria.</measure>
    <time_frame>Before and after treatment with paclitaxel.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breast-conserving surgery: tumorectomy or quadrantectomy with or without lymphadenectomy versus mastectomy.</measure>
    <time_frame>At surgery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Axillary node involvement after primary chemotherapy.</measure>
    <time_frame>At surgery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction measured by echocardiography or MUGA.</measure>
    <time_frame>At baseline, every 2 doxorubicine cycles and before surgery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac sign/symptom questionnaire.</measure>
    <time_frame>At baseline, every 2 doxorubicine cycles and before surgery.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival at 5 years after surgery and overall survival at 5 years after study entry.</measure>
    <time_frame>Until 5 years after surgery.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Primary chemotherapy regimen consisting of four cycles of pegylated-liposomal doxorubicine at 35 mg/m² IV plus CPM 600 mg/m² on Day 1 every 4 weeks followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal pegylated doxorubicine</intervention_name>
    <description>Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Caelyx</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed invasive breast cancer (tumor &gt; 2 cm).

          -  Estrogen receptor-negative or -weakly positive tumors (less than 50% of cells), as
             evaluated using IHC.

          -  Risk factors for developing anthracycline-induced cardiomyopathy.

        Exclusion Criteria:

          -  Severe heart failure (NYHA Class III or IV) .

          -  Metastatic disease.

          -  LVEF &lt; 45%.

          -  Pregnant or breast-feeding patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Gil, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Català d'Oncologia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Català d'Oncologia</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llàtzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Illes Balears</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Sant Joan de Reus</name>
      <address>
        <city>Reus</city>
        <state>Tarragona</state>
        <zip>42301</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Gil-Gil MJ, Bellet M, Morales S, Ojeda B, Manso L, Mesia C, Garcia-Martínez E, Martinez-Jáñez N, Melé M, Llombart A, Pernas S, Villagrasa P, Blasco C, Baselga J. Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study. Breast Cancer Res Treat. 2015 Jun;151(3):597-606. doi: 10.1007/s10549-015-3415-2. Epub 2015 May 16.</citation>
    <PMID>25981896</PMID>
  </reference>
  <results_reference>
    <citation>Gil MJ, Bellet MC, Llombart, Ojeda B, Manso L, Mesia C, Morales S, García-Martinez H, Martínez N, Melé M, Fernández-Ortega A, Baselga J. Pegylated Liposomal Doxorubicin (PLD) as Primary Treatment in Estrogen Receptor (ER) and HER2 Poor Breast Cancer and Risk of Developing Cardiotoxicity or Elderly Patients (pt). Results from the Phase II CAPRICE Study. Cancer Research 71(24 Suppl.): 403s, 2011.(CTRC-AACR San Antonio Breast Cancer Symposium)</citation>
  </results_reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2007</study_first_submitted>
  <study_first_submitted_qc>November 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2007</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast</keyword>
  <keyword>Cancer</keyword>
  <keyword>Anthracyclines</keyword>
  <keyword>Cardiopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

